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Abstract 
Background: Human Papillomavirus is responsible for over 99 % of cervical cancers and is associated with cancers 
of the head and neck. The currently available prophylactic vaccines against HPV do not generate therapeutic effects 
against established HPV infections and associated lesions and disease. Thus, the need for a therapeutic vaccine capa‑
ble of treating HPV‑induced malignancies persists. Synthetic long peptides vaccination is a popular antigen delivery 
method because of its safety, stability, production feasibility, and its need to be processed by professional antigen 
presenting cells before it can be presented to cytotoxic CD8+ T lymphocytes. Cancers in the buccal mucosa have 
been shown to elicit cancer‑related inflammations that are capable of recruiting inflammatory and immune cells to 
generate antitumor effects. In the current study, we evaluated the therapeutic potential of synthetic HPV long peptide 
vaccination in the absence of adjuvant in the TC‑1 buccal tumor model.
Result: We show that intratumoral vaccination with E7 long peptide alone effectively controls buccal TC‑1 tumors 
in mice. Furthermore, we observed an increase in systemic as well as local E7‑specific CD8+ T cells in buccal tumor‑
bearing mice following the vaccination. Finally, we show that induction of immune responses against buccal tumors 
by intratumoral E7 long peptide vaccination is independent of CD4+ T cells, and that the phenomenon may be 
related to the unique environment associated with mucosal tissues.
Conclusion: Our results suggest the possibility for clinical translation of the administration of adjuvant free therapeu‑
tic long peptide vaccine as a potentially effective and safe strategy for mucosal HPV‑associated tumor treatment.
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Background
It is now clear that human papillomavirus (HPV) infec-
tion is responsible for over 99  % of all cervical cancers, 
and is also associated with many other anogenital malig-
nancies including vaginal and anal cancers [1]. In addi-
tion, the prevalence of HPV infection in head and neck 
cancers increased significantly within the past decade, 
with approximately 75  % of diagnosed oropharyngeal 
cancers corresponding with HPV infection [2]. Among 
all HPV subtypes, the high-risk oncogenic HPV sub-
types, predominantly HPV type 16, are responsible for 
the majority of HPV associated cancer [3, 4]. The known 
etiology of HPV-associated diseases provides an excel-
lent opportunity to develop vaccines against the high-
risk HPV types. Encouragingly, there have been several 
successes in the development of prophylactic vaccines 
against disease-causing HPV subtypes [5]. However, 
these prophylactic vaccines can only prevent infec-
tions and do not generate therapeutic effects against 
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established HPV infections and HPV-associated lesions 
[6]. Thus, the urgent need for the development of a thera-
peutic vaccine capable of treating HPV-induced malig-
nancies persists.
To date, several clinical trials have been conducted 
using HPV-16 encoded oncoproteins E6 and E7 as tar-
gets of immunotherapy to treat HPV-induced cancers 
[7–10]. Among different therapeutic vaccine designs, 
peptide-based vaccines containing minimal epitopes of 
oncoproteins E6 and E7 have been popular and promis-
ing due to their safety, stability, and production feasi-
bility [9, 11–13]. However, some limitations to peptide 
vaccines dampen their application efficacy. Importantly, 
short peptides may be directly loaded onto any MHC I 
molecules on the surface of cells, including those that are 
not professional antigen presenting cells (APCs). This 
may result in interaction between T-cell receptor and 
MHC I—antigen peptide complex in the absence of co-
stimulation, causing T-cell anergy and immune tolerance 
[13]. To overcome this issue and increase the efficacy of 
the peptide vaccine, the length of the peptide antigen has 
been increased [14, 15]. The synthetic long peptides are 
too large for the direct loading onto MHC I molecules on 
the surface of cells, thus requiring the peptide to be taken 
up and processed before the epitope can be presented 
on MHC I molecules, which is a process unique to the 
professional APCs. The professional APCs, such as the 
dendritic cells (DCs), can also provide the co-stimulatory 
signals during antigen presentation, ensuring quality T 
cell activation [16, 17].
Despite the improved antigen presentation process 
of the synthetic long peptide vaccine, the issue of poor 
immunogenicity remains. Typically, additional adjuvant 
or immunostimulant is required to induce the desired 
immune responses for vaccines incorporating synthetic 
peptides of a target antigen [9]. It is well known that 
malignant tumors, including squamous cell carcino-
mas of head and neck, are strongly associated with local 
inflammation [18, 19]. These cancer-related inflamma-
tions trigger the release of cytokines and the recruitment 
of inflammatory and immune cells, which could lead to 
the induction of either immune suppression or anti-
tumor immunity [20, 21]. Thus, the inflammatory nature 
of cancer may potentially serves as self-adjuvant capable 
of inducing the antigen-specific immune responses fol-
lowing synthetic long peptide vaccination.
In the current study, we evaluated the therapeutic 
potential of a synthetic HPV long peptide vaccine in the 
absence of adjuvant in the TC-1 buccal tumor model. We 
showed that intratumoral (I.T.) vaccination with HPV-16 
E7aa 43-62 synthetic long peptide lead to enhanced anti-
tumor effect in buccal tumor-bearing mice in the absence 
of adjuvant administration. Furthermore, we observed an 
increase in the number of E7-specific CD8+ T cells in the 
peripheral blood, spleen, and the buccal mucosa tissue. 
We also observed that the antitumor effect of the syn-
thetic long peptide vaccination is CD8+ T cells depend-
ent and CD4+ T cells independent. We also showed that 
in comparison to subcutaneous tumor model, intratu-
moral synthetic long peptide vaccination in the absence 
of adjuvant lead to the generation of superior E7-specific 
CD8+ T cell response as well as more potent therapeu-
tic antitumor effects against tumors located in the buc-
cal mucosal region. Finally, we demonstrated that the 
observed therapeutic effects generated by intratumoral 
E7 long peptide vaccination in the buccal area are abol-
ished upon deletion of toll-like receptor 4. Our results 
indicate that adjuvant free therapeutic long peptide vac-
cination is an effective and safe therapeutic strategy for 
treating tumors located in the mucosa.
Results
Intratumoral administration of synthetic HPV long peptide 
vaccine in the buccal area generates potent antitumor 
responses
First, we assessed the antitumor effect generated by 
intratumoral synthetic HPV-16 E7aa 43-62 peptide vac-
cination in the HPV-16 E7-expressing TC-1 buccal tumor 
model. C57BL/6 mice (five per group) were challenged 
with 3 × 104 TC-1-Luc cells in the right buccal area, then 
vaccinated I.T. with or without synthetic HPV-16 E7aa 
43-62 peptide 3 days after for 4 times with a 4 day inter-
val (Fig. 1a). As shown in Fig. 1b, mice vaccinated with E7 
peptide generated significantly better antitumor effects 
which resulted in tumor control as measured by biolumi-
nescence intensity compared to untreated mice. In addi-
tion, the vaccinated mice demonstrated longer survival 
compared to untreated mice (Fig. 1c). However, when the 
tumor bearing mice were vaccinated with non-specific 
CTL peptide (OVA 241-270), neither effective tumor 
control (Additional file 1: Figure S1A–B) nor prolonged 
survival (Additional file  1: Figure S1C) were observed. 
These data indicated that intratumoral synthetic E7 long 
peptide vaccination leads to effective E7-expressing buc-
cal tumor control in the absence of additional adjuvant.
Intratumoral administration of synthetic HPV long peptide 
vaccine in the buccal area leads to generation of systemic 
and local E7‑specific CD8+ T cell responses
We next evaluate the potential of I.T. E7aa 43-62 long 
peptide vaccination in generating antigen-specific adap-
tive immune responses. C57BL/6 mice (five per group) 
were challenged with 3 × 104 TC-1-Luc cells in the right 
buccal area, then vaccinated I.T. with or without syn-
thetic E7aa 43-62 peptide 3 days after for four times with 
a 4  day interval. Peripheral blood, spleen, and tumors 
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of the tumor bearing mice were harvested 21 days after 
tumor challenge and either stained with E7 tetramer or 
stimulated with E7 peptide followed by IFN-γ staining 
and analyzed by flow cytometry. As shown in Fig.  2a, 
b, more E7-specific CD8+ T cells were induced in the 
peripheral blood of tumor bearing mice vaccinated with 
E7aa 43-62 long peptide compare to mice without vac-
cination. Mice vaccinated with E7aa 43-62 long peptide 
also generated more IFN-γ secreting CD8+ T cells in 
spleen compared to untreated mice (Fig.  2c). Further-
more, as shown in Fig.  2d, mice vaccinated with E7aa 
43-62 long peptide also generated more E7-specific 
CD8+ in the buccal tumor compared to untreated mice. 
Taken together, these data suggest that intratumoral syn-
thetic long peptide vaccination can induce potent sys-
temic E7-specific CD8+ T cell generation as well as local 
antigen-specific CD8+ T cells accumulation in buccal 
tumor in the absence of adjuvant.
The synthetic HPV long peptide vaccine generates potent 
antitumor effects against HPV‑16 E7 expressing tumors 
in CD4‑depleted mice but not in CD8‑depleted mice
Next, we sought to determine which immune cell popu-
lation is predominately responsible for the generation 
of antitumor effects following synthetic E7 long pep-
tide vaccination. We repeated the experiment in both 
CD4 depleted mice and CD8 depleted mice. As shown 
in Fig.  3b, c, CD8 depleted mice showed significantly 
increased tumor growth as measured by bioluminescence 
intensity as well as reduction in survival even after syn-
thetic long peptide vaccination compared to CD8 intact 
mice, at a level similar to the untreated mice. However, 
the treatment effects of tumor reduction and prolonged 
survival were observed in CD4 depleted, E7 long peptide 
vaccinated mice compared to mice without CD4 deple-
tion (Fig. 3d, e). These results indicate that the antitumor 
responses elicited by I.T. vaccination of E7 long peptide 
in the absence of adjuvants are CD8+ T cells dependent 
and CD4+ T cells independent.
Intratumoral administration of synthetic HPV long peptide 
vaccine leads to better generation of E7‑specific CD8+ 
T cells and more potent antitumor effects against buccal 
mucosal tumor compared to subcutaneous tumor
Finally, we tested whether I.T. synthetic E7 long peptide 
vaccination without adjuvant can also elicit an antitu-
mor immune response in other tumor models. C57BL/6 
mice (five per group) were challenged with TC-1-Luc 
cells either submucosally in the right buccal area or sub-
cutaneously in the abdomen and then vaccinated I.T. 
with synthetic E7 long peptide. 21 days after tumor chal-
lenges, the spleen of mice were harvested and stimulated 
with E7 peptide followed by IFN-γ staining and analyzed 
by flow cytometry. As shown in Fig. 4a, b, I.T. synthetic 
Fig. 1 Characterization of antitumor effect in tumor bearing mice treated with intratumoral synthetic HPV‑16 E7aa 43‑62 long peptide vaccination 
in buccal mucosal region. 3 × 104 TC‑1‑Luc cells were submucosally injected into the right buccal area of C57BL/6 mice (five per group). Three days 
after tumor injection, mice were vaccinated intratumorally with or without 50 μg of synthetic HPV‑16 E7aa 43‑62 peptide for four times in a 4‑day 
intervals. a Schematic diagram of treatment regimens. b Line graph depicting the change in mean luminescence intensity of tumor bearing mice 
after tumor injection (mean ± SD). c Kaplan–Meier survival analysis of mice
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long peptide vaccination in buccal tumor-bearing mice 
generated significantly higher amount of IFN-γ secreting 
CD8+ T cells in the spleen compared to naïve mice, mice 
received buccal vaccination alone or buccal tumor chal-
lenge alone, whereas there were no significant differences 
in the number of IFN-γ secreting CD8+ T cells in spleen 
of mice receiving subcutaneous treatments. Furthermore, 
mice challenged with buccal tumor injection and treated 
with I.T. synthetic E7 long peptide vaccination showed 
significantly reduced tumor growth compared to mice 
without treatment, whereas I.T. synthetic E7 long peptide 
vaccination was not able to control tumor growth in mice 
challenged with subcutaneous tumor injection (Fig.  5a, 
b). These data demonstrated that I.T. synthetic E7 long 
peptide vaccination without adjuvant supplementation is 
more effective in the treatment of tumors located in the 
buccal mucosa than in the treatment of tumors located in 
the subcutaneous abdomen.
Knocking out toll‑like receptor 4 abolishes the therapeutic 
effect of intratumoral synthetic HPV long peptide 
vaccination
As mentioned in the introduction, the inflammatory 
nature of tumors located in the buccal area may serve 
as an adjuvant to induce antitumor immunity. Thus, 
the innate immune environment of the buccal area 
may play a role in mediating the generation of antigen-
specific CD8+ T cell responses and anti-tumor effects 
observed from previous experiments involving intratu-
moral synthetic E7 long peptide vaccination against buc-
cal TC-1 tumors. To examine the importance of innate 
immune responses in the observed treatment effect, 
we repeated the same experiment described in Fig.  1 
in C57BL/10ScNJ (TLR4 deficient) mice. As shown in 
Fig.  6, TLR4 −/− mice treated with intratumoral syn-
thetic E7 long peptide vaccination did not generate sig-
nificant antitumor effect against buccal TC-1 tumor to 
Fig. 2 Characterization of systemic E7‑specific CD8+ T cells and local E7‑specific activated CD8+ T cells in tumor bearing mice. 3 × 104 TC‑1‑Luc 
cells were submucosally injected into the right buccal area of C57BL/6 mice (five per group). Three days after tumor injection, mice were vacci‑
nated intratumorally with or without 50 μg of synthetic HPV‑16 E7aa 43‑62 peptide for four times in a 4‑day intervals. 21 days after tumor injection, 
peripheral blood was collected and the spleen and tumor were harvested. Cells obtained from the peripheral blood and tumor were stained with 
PE‑conjugated HPV16 H‑2D‑RAHYNIVTF tetramer and APC‑conjugated CD8 monoclonal antibody followed by flow cytometry analysis. Spleeno‑
cytes were stimulated with HPV16 E7aa49‑57 peptide in the presence of GolgiPlug and IFN‑γ‑secreting CD8+ T cells were detected by intracellular 
cytokine staining followed by a flow cytometry analysis. a Representative flow cytometry images showing the amount of E7‑specific CD8+ T cells 
per 1 × 105 lymphocytes in the peripheral blood of various groups. b Bar graph depicting the amount of E7‑specific CD8+ T cells per 1 × 105 
lymphocytes in the peripheral blood of various groups (mean ± SD). c Bar graph depicting the amount of IFN‑γ positive lymphocytes per 1 × 105 
splenocytes (mean ± SD). d Bar graph depicting the percentage of E7‑specific CD8+ T cells in all lymphocytes in the buccal tumor (mean ± SD)
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prolong survival compared to the control, untreated 
mice. Buccal tumor-bearing mice with intact TLR4 func-
tion and received intratumoror synthetic E7 long pep-
tide vaccination, however, survived significantly longer 
than TLR4 deficient mice who received the same treat-
ment. This observation supports the hypothesis that the 
innate immune system of the buccal area is important for 
the immune responses and anti-tumor effects elicited by 
intratumoral E7 long peptide vaccination against tumors 
located in the buccal mucosa area.
Discussion
In the current study, we examined the effects of adju-
vant free, I.T. synthetic E7 long peptide vaccination on 
the generation of antigen-specific immune responses 
and antitumor effects. We observed that following I.T. 
synthetic E7 long peptide vaccination, the buccal tumor-
bearing mice exhibited significant increase in systemic 
and local E7-specific CD8+ T cells, effectively control-
ling the tumor growth. In addition, we found that the 
antitumor effects generated by E7 long peptide vaccine 
is predominantly mediated by the CD8+ T cells and not 
by CD4+ T cells. Finally, we show that I.T. synthetic E7 
long peptide vaccination without adjuvant elicited a bet-
ter E7-specific CD8+ T cell response and more potent 
antitumor effects against tumors located in the buc-
cal mucosa than to tumors located in the subcutaneous 
abdomen.
Fig. 3 Effect of CD4+ or CD8+ T cell depletion on the antitumor response of synthetic HPV‑16 E7aa 43‑62 long peptide vaccine. 100 μg of purified 
rat monoclonal antibody GK1.5 (anti‑CD4) or mAB 2.43 (anti‑CD8) were injected intraperitoneally 2 days before tumor injection. The injections 
were repeated once per day for 2 days until the day of tumor challenge. On the day of tumor challenge, 3 × 104 TC‑1‑Luc cells were submucosally 
injected into the right buccal area of C57BL/6 mice (five per group). Three days after tumor injection, mice were vaccinated intratumorally with or 
without 50 μg of synthetic HPV‑16 E7aa 43‑62 peptide for four times in a 4‑day intervals. Mice also continued to receive anti‑CD4 or anti‑CD8 anti‑
body injections once every week after tumor injection. a Schematic diagram of treatment regimens. b Line graph depicting the change in mean 
luminescence intensity of tumor bearing mice after tumor injection with or without CD8 depletion (mean ± SD). c Kaplan–Meier survival analysis of 
mice in CD8 depletion experiment. d Line graph depicting the change in mean luminescence intensity of tumor bearing mice after tumor injection 
with or without CD4 depletion (mean ± SD). e Kaplan–Meier survival analysis of mice in CD4 depletion experiment. NS indicates not significant
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Of note, we demonstrated a difference in the ability of 
E7 long peptide vaccine in generating potent antigen-
specific immune responses and antitumor effects when 
vaccinated I.T. against buccal tumors compared to when 
vaccinated I.T. against subcutaneous tumors (Figs. 4 and 
5). This observation is supported by previous data. We 
have previously explored the employment of a sulfated 
polysaccharide compound from red algae, carrageenan, as 
adjuvant to generate antigen-specific immune responses 
and antitumor effects following subcutaneous E7 pep-
tide vaccination [22]. The experiment demonstrated that 
subcutaneous E7 peptide vaccination alone without car-
rageenan administration did not lead to generation and 
activation of E7-specific CD8+ T cell immune response, 
which correspond to limited protective and therapeu-
tic antitumor effects. In a separate study, we explored 
the adjuvant effect of chemotherapy in eliciting antigen-
specific antitumor response and showed that I.T. vaccina-
tion of E7 peptide without cisplatin administration did 
not lead to effective control of subcutaneous tumors or 
the generation of potent E7-specific immune responses 
[23]. We explored the potential reasons for the phenom-
ena observed in these previous studies, and showed that 
there was significantly less CD11c+ DCs accumulation 
in tumor as well as DCs migration to the lymph nodes 
when vaccinated I.T. with E7 peptide only without admin-
istration of adjuvant [22, 23]. Furthermore, DCs isolated 
from mice treated with E7 peptide vaccine alone express 
significantly less costimulatory molecules compared to 
those isolated from mice treated with both peptide vacci-
nation and adjuvant administration, which translates into 
a lower ability to activate E7-specific CD8+ T cells. In 
contrast, a previous study has shown that buccal immu-
nization with measles virus nucleoprotein (NP) alone is 
capable of eliciting a NP-specific CD8+ CTL response 
[24]. Furthermore, the study observed a rapid recruitment 
of DCs into the buccal mucosa after NP vaccination. In 
this study, we showed that the innate immune system reg-
ulated by TLR4 plays a significant role in eliciting the anti-
tumor responses against buccal TC-1 tumor (Fig. 6). The 
differences in the tissue environment and the ability to 
recruit APCs to the local area may account for the differ-
ence in the generation of immune responses and antitu-
mor effects between I.T. vaccination against buccal tumor 
versus I.T. vaccination against subcutaneous tumor. The 
trafficking of immune cells to the tumor location before 
and after I.T. E7 peptide vaccination in the buccal mucosa 
or subcutaneous abdomen should be further explored in 
future studies.
One key finding of the current study is that the exper-
iments involving synthetic E7 long peptide vaccination 
were conducted without administration of supplement-
ing adjuvants. Many studies have been performed to 
explore different approaches to elicit potent immune 
responses and antitumor effects through adjuvant-free 
vaccination [25–27]. Even though administration of 
Fig. 4 Comparison of HPV‑16 E7 specific CD8+ T cell responses induced by synthetic HPV‑16 E7aa 43‑62 long peptide vaccine in various tumor 
model. C57BL/6 mice (five per group) received either 3 × 104 TC‑1‑Luc cells injection submucosally into the right buccal area or 1 × 105 TC‑1‑Luc 
cells injection subcutaneously into the abdomen. Three days after tumor injection, mice were vaccinated intratumorally with or without 50 μg of 
synthetic HPV‑16 E7aa 43‑62 peptide for four times in a 4‑day intervals. 21 days after tumor injection, spleenocytes were harvested and stimulated 
with HPV16 E7aa49‑57 peptide in the presence of GolgiPlug and IFN‑γ‑secreting CD8+ T cells were detected by intracellular cytokine staining fol‑
lowed by a flow cytometry analysis. a Bar graph depicting the amount of IFN‑γ positive lymphocytes per 3 × 105 splenocytes for buccal treatments 
(mean ± SD). b Bar graph depicting the amount of IFN‑γ positive lymphocytes per 3 × 105 splenocytes for subcutaneous treatments (mean ± SD). 
NS indicates not significant
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adjuvants can elicit stronger immune responses, many 
substances with adjuvant effects have also been shown 
to have negative impact on tumor treatment [28, 29], to 
cause T cells dysfunction and retention [30, 31], to have 
neurotoxicity [32], or to induce autoimmunity [33]. 
Thus, identifying appropriate adjuvants that are both 
safe and effective when incorporated into vaccination 
strategies is a significant concern. Our study suggests 
the potential utilization of the natural immunogenic 
characteristics of mucosal tissue to elicit potent anti-
gen-specific immune responses as well as therapeutic 
antitumor effects without administration of adjuvants, 
thus reducing the safety concerns for vaccination.
Conclusion
In summary, we found that intratumoral therapeutic 
synthetic E7 long peptide vaccination resulted in both 
systemic and local increase of antigen-specific CD8+ 
T cells in mice bearing buccal tumors without the 
need to administer additional adjuvants to enhance 
the immunogenicity of the vaccine. This study sug-
gests the possibility of clinical translation of admin-
istration of an adjuvant-free therapeutic HPV vaccine 
to generate potent cell-mediated immune responses 
and antitumor effects against HPV-associated lesions 




Six- to eight-week-old female C57BL/6 mice were pur-
chased from the Charles Rivers Laboratories (Frederick, 
MD, USA). Female C57BL/10ScNJ mice carrying a spon-
taneous deletion of Tlr4 gene were obtained from The 
Jackson Laboratory (Bar Harbor, Maine, USA). All ani-
mal procedures were performed according to approved 
protocols at the Johns Hopkins Institutional Animal Care 
and Use Committee in accordance with recommenda-
tions for the proper use and care of laboratory animals.
Cells
TC-1 cells expressing luciferase (TC-1-Luc) were gener-
ated and cultured using methods described previously. 
[34, 35]
Synthetic long peptide vaccine
The synthetic long-peptide vaccine used in this study, 
E7aa 43-62, consists of synthetic peptide resembling 
Fig. 5 Comparison of antitumor effects induced by synthetic HPV‑16 
E7aa 43‑62 long peptide vaccine in various tumor model. C57BL/6 
mice (five per group) received either 3 × 104 TC‑1‑Luc cells injection 
submucosally into the right buccal area or 1 × 105 TC‑1‑Luc cells 
injection subcutaneously into the abdomen. Three days after tumor 
injection, mice were vaccinated intratumorally with or without 50 μg 
of synthetic HPV‑16 E7aa 43‑62 peptide for four times in a 4‑day 
intervals. a Line graph depicting the change in mean lumines‑
cence intensity of tumor bearing mice after buccal tumor injection 
(mean ± SD). b Line graph depicting the change in mean lumines‑
cence intensity of tumor bearing mice after subcutaneous tumor 
injection (mean ± SD)
Fig. 6 Effect of TLR4 Knockout on the antitumor response of syn‑
thetic HPV‑16 E7aa 43‑62 long peptide vaccine. 3 × 104 TC‑1‑Luc cells 
were submucosally injected into the right buccal area of C57BL/6 
or C57BL/10ScNJ (TLR4−/−) mice (five per group). Three days after 
tumor injection, mice were vaccinated intratumorally with or without 
50 μg of synthetic HPV‑16 E7aa 43‑62 peptide for four times in a 
4‑day intervals. Figure represents the Kaplan–Meier survival analysis 
of mice in TLR4 knockout experiment
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43-62 amino acid peptide chain of HPV-16 E7 antigen. 
This synthetic peptide construct contains an H-2Db-
restricted E7 epitope (aa 49-57), and its immunogenicity 
has been demonstrated in our previous study [36]. The 
synthetic peptide was prepared at 95 % purity. No addi-
tional adjuvant was included in the vaccine.
For non-specific peptide vaccination experiment, CTL 
peptide OVA 241-270 (SMLVLLPDEVSGLEQLESIINF
EKLTEWTS(OVA30)) were used. This peptide has been 
previously described [14].
In vivo tumor treatment experiments
For the establishment and treatment of orophoryn-
geal tumor, 3 ×  104 TC-1-Luc cells were submucosally 
injected into the right buccal area of C57BL/6 or 
C57BL/10ScNJ mice. Tumor growth was confirmed by 
IVIS2000 bioluminescence imaging system. Three days 
after tumor injection, mice were vaccinated intratumor-
ally with 50 μg of synthetic HPV-16 E7aa 43-62 peptide 
or 50  μg of CTL peptide OVA 241-270. Mice received 
same booster vaccination at 4-day intervals for a total 
of three boosters. The luminescence intensity of tumor 
was measured routinely with IVIS imaging machine.
For the establishment and treatment of abdominal 
tumor, 1  ×  105 TC-1-Luc cells were subcutaneously 
injected into the abdomen of C57BL/6 mice. Mice then 
received intratumoral vaccination using the same treat-
ment schedule as described for the orophoryngeal tumor 
model. Tumor growth was monitored routinely by palpa-
tion and inspection.
CD4/CD8 depletion
Hundred microgram of purified rat monoclonal anti-
body GK1.5 (anti-CD4) or mAB 2.43 (anti-CD8) were 
injected intraperitoneally 2 days before tumor injection. 
The injections were repeated once per day for 2  days 
until the day of tumor challenge. Mice were then inocu-
lated with TC-1-Luc cells and vaccinated with synthetic 
HPV-16 E7aa 43-62 peptide following the same treat-
ment schedule as described earlier for the oropharyn-
geal tumor model. Mice continued to receive anti-CD4 
or anti-CD8 antibody injections once every week after 
tumor injection.
Peripheral blood cell, splenocyte, and tumor infiltrating 
lymphocyte preparation
Twenty-one days after tumor injection, peripheral blood 
was obtained from the mice treated with various treatment 
regimen and the spleen and TC-1 tumors of the mice were 
harvested. For the preparation of splenocytes, the spleen 
was meshed through a 70 μm nylon filter mesh. The sple-
nocytes and peripheral blood cells were treated with ACK 
lysis buffer to lyse the red blood cells, the cells were then 
washed and viable cells were identified using trypan blue 
dye exclusion. TC-1 tumors were surgically excised using 
sterile technique, placed in RPMI-1640 medium contain-
ing 100 U/ml penicillin and 100 μg/ml streptomycin and 
washed with PBS. The solid tumors were then minced 
into 1- to 2-mm pieces and immersed in serum-free 
RPMI-1640 medium containing 0.05 mg/ml collagenase I, 
0.05 mg/ml collagenase IV, 0.025 mg/ml hyaluronidase IV, 
0.25 mg/ml DNase I, 100 U/ml penicillin, and 100 μg/ml 
streptomycin and incubated at 37  °C with periodic agita-
tion. The tumor digest was then filtered through a 70 μm 
nylon filter mesh to remove undigested tissue fragments. 
The resultant single tumor cell suspensions and tumor-
infiltrating lymphocytes were washed twice in Hank’s buff-
ered salt solution (HBSS) (400  g  for 10  min), and viable 
cells were determined using trypan blue dye exclusion.
Tetramer analysis of E7‑specific CD8+ T cells in tumor 
bearing mice
Cells harvested from the peripheral blood and TC-1 
tumors were stained with phycoerythrin (PE)-conju-
gated HPV16 H-2D-RAHYNIVTF tetramer combined 
with surface staining using APC-Alexa Fluor-conjugated 
anti-CD8 (BD Pharmingen). Cells were analyzed on a BD 
FACSCalibur collecting 500,000 events.
Intracellular cytokine staining and flow cytometry analysis
The cells harvested from the spleen of mice treated with 
various treatment regiments were incubated 0.1 μg/ml of 
HPV-16 E7 peptide containing an MHC class I epitope 
(aa49-57, RAHYNIVTF) in the presence of GolgiPlug 
(BD Pharmingen, San Diego, California, USA). The stim-
ulated cells were then washed once with FACScan buffer 
and stained with phycoerythrin-conjugated monoclonal 
rat anti-mouse CD8a (clone 53.6.7). Cells were subjected 
to intracellular cytokine staining using the Cytofix/Cytop-
erm kit according to the manufacture’s instruction (BD 
Pharmingen). Intracellular IFN-γ was stained with FITC-
conjugated rat anti-mouse IFN-γ. All antibodies were pur-
chased from BD Pharmingen. Flow cytometry analysis was 
done using FACSCalibur with CellQuest software (BD Bio-
science). FITC Rat IgG1, κ Isotype Control (Clone R3-34) 
was purchased from BD Pharmingen (Cat.# 554684).
Statistical analysis
All data presented in this study are expressed as 
mean  ±  SD. At least three samples per group were 
included in each of these experiments. Flow cytometry 
data and results of tumor treatment experiments were 
evaluated by analysis of variance (1-way ANOVA) and 
the Tukey–Kramer test. Individual data points were com-
pared by student’s t-test. For all analysis, p values <0.05 
were considered significant.
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